Edwards Lifesciences Corp. (EW) has disclosed a new risk, in the Natural and Human Disruptions category.
Edwards Lifesciences Corp. faces significant business risk due to public health crises, which exert overwhelming pressure on hospital systems and supply chains integral to their operations. The unpredictable nature of pandemics and epidemics, exemplified by COVID-19, presents a substantial threat. These events are fraught with uncertainty and are challenging to forecast, potentially leading to severe adverse effects on Edwards Lifesciences’ business performance and financial stability. Such health emergencies can disrupt the continuity of their services and impede revenue generation, underscoring a critical vulnerability in their business model.
The average EW stock price target is $89.86, implying 4.17% upside potential.
To learn more about Edwards Lifesciences Corp.’s risk factors, click here.
